{
    "2018-11-19": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids",
                "features": {
                    "keywords": [
                        "VRTX",
                        "Positive CHMP Opinion",
                        "Orkambi",
                        "Kids"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "CLASS ACTION UPDATE for ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "features": {
                    "keywords": [
                        "ABBV",
                        "ALNY",
                        "Class Action",
                        "Shareholders"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "AbbVie Inc.",
                        "Class Action Lawsuit",
                        "Losses"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Should Value Investors Consider AbbVie (ABBV) Stock Now?",
                "features": {
                    "keywords": [
                        "Value Investors",
                        "ABBV",
                        "Stock"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018",
                "features": {
                    "keywords": [
                        "Bronstein",
                        "Gewirtz & Grossman",
                        "Class Action",
                        "ABBV",
                        "Lead Plaintiff Deadline"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "How Is Bausch Health’s Ortho Dermatologics Performing?",
                "features": {
                    "keywords": [
                        "Bausch Health",
                        "Ortho Dermatologics",
                        "Performing"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}